A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02761616

Enrollment

Registered

2016-05-04

Start date

2016-06-30

Completion date

2016-11-30

Last updated

2017-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This is a retrospective, and observational cohort study to determine the proportion of breast cancer first relapses, that are biopsied. The duration of the study will be approximately 24 months.

Interventions

OTHEReBC treated participants

No intervention administered in this retrospective observational study.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participants with histologically confirmed breast cancer treated for early breast cancer (eBC) with first metastatic relapse disease in the period from January 1, 2014 and December 31, 2015

Exclusion criteria

Not Applicable

Design outcomes

Primary

Measure	Time frame
Percentage of biopsied participants with metastatic relapse	Approximately up to 24 months

Secondary

Measure	Time frame
Percentage of biopsied and non-biopsied participants at first relapse metastatic breast cancer (mBC) for each metastatic site	Approximately up to 24 months
Percentage of biopsied participants at first relapse mBC according to each biopsy method	Approximately up to 24 months
Percentage of biopsied and non- biopsied participants at first relapse mBC for each molecular profile of primary tumor	Approximately up to 24 months
Percentage of biopsied participants at first relapse mBC for each molecular profile of biopsied metastases	Approximately up to 24 months
Percentage of non-biopsied participants at first relapse according to different reasons for not performing a biopsy of the metastasis	Approximately up to 24 months
Time to relapse	Approximately up to 24 months
Percentage of participants with type of first line therapy selected for metastatic disease	Approximately up to 24 months
Percentage of participants influenced with biopsy in mBC	Approximately up to 24 months
Percentage of biopsied and non- biopsied participants at first relapse mBC for each systemic treatment scheme in the adjuvant and in the metastatic setting	Approximately up to 24 months
Percentage of biopsied participants at first relapse mBC with same and different molecular profiles between primary tumor and metastasis for each molecular profile	Approximately up to 24 months

Countries

Argentina

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026